Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2023-12-21 Regulatory Filings
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
IRLAB får finansiering från The Michael J. Fox Foundation för utveckling av IRL757 för behandling av apati
Regulatory Filings Classification · 100% confidence The document is a press release dated December 21, 2023, announcing that IRLAB Therapeutics AB has received funding (over $2 million USD) from The Michael J. Fox Foundation (MJFF) to support the Phase I clinical trial of their drug candidate IRL757 for treating apathy in Parkinson's disease. The text explicitly mentions the funding agreement, the purpose (Phase I study), and concludes with a standard regulatory disclosure: "Denna information är sådan information som IRLAB Therapeutics är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This structure—a formal announcement of a significant corporate event (funding/financing) that is not a full financial report (10-K, IR) or a dividend notice—best fits the 'Capital/Financing Update' category. It is a direct announcement about securing capital/funding for development, not a general regulatory filing (RNS) or a management change (MANG).
2023-12-21 Swedish
Valberedningen utsedd inför IRLAB:s årsstämma 2024
Board/Management Information Classification · 99% confidence The document is a press release written in Swedish announcing the appointment of the Nomination Committee (Valberedningen) members ahead of the 2024 Annual General Meeting (årsstämma 2024). This announcement concerns the preparation for the AGM, specifically regarding the body responsible for nominating board members. While it relates to the AGM, the core content is the formation of the nomination committee, which is a governance/board-related activity. However, the most specific category related to shareholder meetings and associated preparatory bodies is AGM Information (AGM-R) or potentially Governance Information (CGR). Since the text explicitly mentions the 'årsstämma 2024' (AGM 2024) and the composition of the committee that serves that meeting, AGM-R is the most appropriate fit, as it covers materials shared during or in preparation for the AGM. The document is a formal announcement/press release, not the meeting presentation itself, but it directly concerns the AGM process.
2023-11-07 Swedish
Nomination committee appointed for IRLAB’s annual general meeting 2024
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of the nomination committee ahead of the 'annual general meeting (AGM) 2024'. While it relates to the AGM, the core content is an announcement about the composition of a committee responsible for nominating board members and setting proposals for the AGM, which falls under governance and preparatory materials for the meeting. However, the provided definitions do not have a specific code for 'Nomination Committee Appointment'. The closest relevant categories are AGM-R (AGM materials) or CGR (Governance Information). Since the announcement details the structure and members of a committee that directly influences board composition and AGM proposals, it is fundamentally a governance announcement. Given the options, CGR (Governance Information) is a strong fit, but AGM-R (AGM Information) is also plausible as it is directly tied to the upcoming AGM. Since the text is an announcement about the *committee* for the AGM, and not the AGM presentation itself, CGR is slightly more precise for the governance aspect described. However, looking closely at the definitions, AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. This announcement is preparatory material for the AGM. Let's re-evaluate the options based on the primary subject: Nomination Committee appointment. This is a key governance function. If the document were the actual AGM presentation slides, AGM-R would be correct. Since it is an announcement about the committee that *prepares* for the AGM, CGR (Governance Information) is the most accurate fit for the subject matter described (committee structure, shareholder representation). I will select AGM-R as the primary focus is the upcoming AGM, and this committee's work directly feeds into the AGM agenda.
2023-11-07 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for IRLAB Therapeutics covering the period January to September 2023. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet data, as well as detailed management commentary on business operations, clinical trial progress, and strategic outlook. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-10-25 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – September 2023' and contains comprehensive financial statements, including net sales, operating profit, earnings per share, and cash flow data for the specified period. It also includes detailed management commentary, operational updates, and strategic priorities. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2023
2023-10-25 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – juni 2023' (Interim Report January – June 2023) for IRLAB Therapeutics. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet data for the period, as well as detailed management commentary on business operations, clinical trials, and future outlook. It is a formal interim financial report, not an announcement or a summary. H1 2023
2023-08-30 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.